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Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) 
and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF 
mutations are rare events in this type of cancer. However, no data are available on NRAS status in 
SCAC. In this study we analyzed NRAS status (exons 2–4) by Pyrosequencing in a case series of 50 SCAC 
patients previously characterized in our laboratory for KRAS, BRAF, PIK3CA mutations and HPV and 
HIV infections. We found no mutation in NRAS gene. These results confirm that since the principal anti-
EGFR resistance mechanisms are almost absent in SCAC, anti-EGFR agents should be considered for the 
treatment of this type of cancer.
Anal cancer accounts for about 1–5% of all gastrointestinal malignancies, and infection of human papilloma 
virus (HPV) represents the main etiologic factor1. The standard treatment for locoregional disease is combined 
chemoradiation, which is associated with a 3-year disease-free survival of about 70%. Of those patients who 
relapse following chemoradiotherapy (CRT), around 40% undergo salvage therapy with abdominoperineal resec-
tion2. Locally advanced or metastatic disease is still incurable, with only limited responses reported for palliative 
chemotherapy3. New therapeutic approaches are required for these patients.
As EGFR expression in anal carcinoma is observed in a high number of patients (about 80–90% of cases)4–6, 
anti-EGFR drugs have been studied for the treatment of SCAC, showing anti-tumoral activity7–10. The use of 
anti-EGFR monoclonal antibodies (mAb anti-EGFRs) in colorectal cancer has shown that KRAS and NRAS rep-
resent the main resistance mechanisms to this type of treatment and are thus used in clinical practice to select the 
patients who should not be treated with anti-EGFR therapy11. BRAF and PIK3CA could also have a prognostic 
role in determining those patients with a worse outcome12–14. KRAS mutation seems to be a rare event in SCAC. 
Some studies, including a study from our group, have shown that no KRAS mutation is present in SCAC4–6,15,16, 
whereas others have reported rates of KRAS mutation of 1–5%17,18. A low frequency of BRAF mutations has also 
been observed in SCAC, with a rate of 0–5%15,17,18. A higher rate of PIK3CA mutation between 16% and 22%, 
has been observed15,18. However, no correlation with patient prognosis was observed for these mutations, as well 
as for HPV infection. To date, no data are available on the frequency of NRAS mutation in SCAC. In this study 
we analyzed the status of NRAS in a case series of SCAC previously characterized for HPV, KRAS, BRAF and 
PIK3CA.
Materials and Methods
Case Series. We analyzed a case series of 50 consecutive SCAC patients treated with chemotherapy and radi-
otherapy at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS in Meldola and at the 
Medical Oncology Units of Faenza, Ravenna and Macerata Hospitals from March 2001 to August 2012, for whom 
histological material was available. Forty-eight patients received the Nigro scheme with standard dosages19, while 
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the remaining 2 patients underwent treatment with cisplatin plus 5-fluorouracil. This case series was previously 
characterized by our group for HPV infection, KRAS (exons 2–4), BRAF (exons 11 and 15) and PIK3CA (exons 
9 and 20) status15.
The study protocol was reviewed and approved by the Medical Scientific Committee of IRST IRCCS, and 
written informed consent was obtained from patients or from their next of kin for the use of biological samples 
for research purposes. In addition, the experiments in this study were conducted in accordance with approved 
guidelines and regulations.
Mutation analysis. Genomic DNA was extracted from Formalin-fixed paraffin-embedded (FFPE) tumor 
blocks, as previously described15. NRAS (exons 2, 3 and 4) status was analyzed by Pyrosequencing using 
anti-EGFR MoAb response (NRAS status) (Diatech, Jesi, Ancona, Italy), according to the manufacturer’s instruc-
tions. Reactions were run on a PyroMark Q96 ID (Qiagen, Hilden, Germany).
Statistical analyses. Descriptive statistics were reported as frequencies and percentages for categorical vari-
ables and median and range for continuous variables. Progression-free survival (PFS) was calculated from the first 
day of treatment to the date of first observation of disease progression or death resulting from any cause, which-
ever occurred first, or the last follow-up for patients who were still alive and had not progressed. Overall survival 
(OS) was calculated from the first day of treatment to the date of death from any cause or the last follow-up. PFS, 
OS and their 95% confidence intervals (95% CI) were estimated using the Kaplan-Meier life-table method and 
survival curves were compared by the logrank test. Statistical significance was assumed for P < 0.05. Statistical 
analyses were carried out with SAS Statistical software (version 9.4, SAS Institute, Cary, NC, USA).
Results
Clinical-pathological characteristics of SCAC patients included in this study are reported in Table 1. Fifty patients 
(19 males, 31 females) were analyzed. Median age was 62 years (range, 37–87 years). Twenty-nine (58%) patients 
had early stage disease (stage I and II), 19 (38%) had regional nodal involvement (stage III), and 2 (4%) had 
distant metastasis (stage IV). All patients were KRAS (exons 2–4) and BRAF (exons 11 and 15) wild-type (wt), 
whereas 11 showed a PIK3CA mutation (8 at exon 9 and 3 at exon 20). All patients had HPV infection (45 HPV 
type 16 and 5 other HPV types), 6 of which had also HIV infection. All 50 patients resulted wt for codons 12–13 
(exon 2), 58-59-61 (exon 3) and 117–146 (exon 4) of NRAS gene.
At a median follow-up of 50 months (range 2 to 178 months), 11 patients had progressed (7 with local and 4 
with distant relapse) and 10 had died from causes other than SCAC. PFS was 82% (95% CI 71–93) at one year, 
67% (95% CI 53–82) at 3 years, and 52% (95% CI 34–70) at 5 years. OS was 93% (95% CI 86–100) at 1 year, 73% 
(95% CI 60–87) at 3 years, and 52% (95% CI 34–70) at 5 years. (Fig. 1 and Table 2). PFS and OS in relation to 
clinical-pathological characteristics of patients and in accordance to PIK3CA status, HIV and HPV infections 
are reported in Table 2. Tumor grade and size, lymph node involvement and stage were significantly associated 
with PFS and OS. Presence of HIV infection, type of HPV infection and PIK3CA status were not correlated with 
survival.
Discussion
The aim of our study was to analyze the status of NRAS gene in a case series of SCAC patients previously charac-
terized in our laboratory for KRAS, BRAF and PIK3CA genes. To our knowledge, this is the first study to analyze 
NRAS status in SCAC. Given that mutations occurring on KRAS exon 2–4 in colorectal cancer – in addition to 
those occurring on NRAS exon 2–4 – may play a role in determining resistance to moAb-EGFRs11, these molec-
ular characterizations could also be investigated in SCAC in view of the potential usefulness of these antibodies 
in this type of cancer.
Other studies have analyzed the frequency of KRAS, BRAF and PIK3CA mutations in SCAC, showing a very 
low rate of KRAS and BRAF mutations15–18, and a slightly higher frequency of PIK3CA mutation15,18. No corre-
lation between PIK3CA mutation and patients prognosis was reported in this study with an updated follow up, 
confirming what previously stated15.
We demonstrated that no NRAS mutation is present in SCAC and confirmed the absence of potential resist-
ance mechanisms to moAb-EGFR, such as cetuximab or panitumumab. This data, together with previous evi-
dence on KRAS and BRAF, suggest that cetuximab could be a valid treatment strategy in SCAC.
We confirmed that PIK3CA mutations have no prognostic role in this type of cancer, whereas tumor grade and 
size, lymph node involvement and stage are significantly associated with PFS and OS. Moreover, infection of HPV 
16 was significantly associated with a longer PFS but not with OS.
A recent phase I study has demonstrated that the adding of cetuximab to a chemo-radiotherapy with 
5-fluorouracil (5-FU) and mitomycin-C in SCAC induced a complete remission rate of 73% with a relative high 
toxicity10. High toxicity was observed also in other clinical trials20,21, suggesting that the relation between toxicity, 
chemotherapy dosage and radiation techniques should be better clarified to optimize this promising combina-
tion treatment strategy for SCAC. In addition to this data, a recent case report has shown a dramatic response to 
cetuximab in combination with cisplatin and 5-FU in a patient with metastatic anal cancer9.
Moreover, there are no therapies available after progression to cisplatin and 5-FU that can improve survival. 
A case report showed a complete response to cetuximab in monochemotherapy in a patient with refractory met-
astatic anal carcinoma suggesting a possible use in this setting22.
There are numerous similarities between SCAC and head and neck squamous cell carcinoma (HNSCC), both 
in terms of etiology and pathology. In particular, as observed in SCAC, high EGFR expression and a low percent-
age of RAS mutations have also been reported in HNSCC23–25, and this was the basic starting point for research 
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n (%)
Gender
 Female 31 (62)
 Male 19 (38)
Age, years
 < 50 7 (14)
 ≥ 50 and < 70 29 (58)
 ≥ 70 14 (28)
Grade
 G1 2 (4)
 G2 32 (64)
 G3 16 (32)
TNM (T)
 t1-2 27 (54)
 t3-4 23 (46)
Stage
 I 8 (16)
 II 21 (42)
 III 19 (38)
 IV 2 (4)
HIV infection
 Yes 6 (12)
 No 44 (88)
HPV infection
 HPV-16 45 (90)
 Other HPV 5 (10)
PIK3CA status
 wt 39 (78)
 mutated 11 (22)
KRAS status
 wt 50 (100)
 mutated —
BRAF status
 wt 50 (100)
 mutated —
Table 1.  Clinical-pathological characteristics of patients. HIV, human immunodeficiency virus; HPV, 
human papillomavirus. wt, wild type.
Figure 1. Kaplan-Meier survival curves of (A) progression-free survival (PFS) and (B) overall survival (OS).
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into mAb anti-EGFRs in this type of cancer. The approval of cetuximab for the treatment of advanced and meta-
static HNSCC26,27 further reinforces the potential effectiveness of anti-EGFR treatment in SCAC.
A limitation of the study consists in the fact that, due to its retrospective nature, not all information on the 
chemoradiotherapy administered was available, in particular that pertaining to the different radiotherapy dosages 
delivered. Moreover, despite the known disadvantages of a composite endpoint, we decided to use such an end-
point because of the potential underreporting of disease recurrences caused by the non-homogeneous availability 
of follow-up data from the different centers involved in the study.
Our results demonstrated that NRAS gene is wt in SCAC patients. These data, together with those reported on 
KRAS status, seem to confirm the potential usefulness of anti-EGFR drugs in the treatment of SCAC. Results of 
ongoing clinical trials will clarify the tolerability and the efficacy of these agents in combination with conventional 
CRT.
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